Stifel analyst Paul Matteis downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Hold with a price target of $27.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE